U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C65H87N14O19S2.Lu
Molecular Weight 1609.542
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LUTETIUM OXODOTREOTIDE LU-177

SMILES

[177Lu+3].CC(O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN3CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC3)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N[C@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O

InChI

InChIKey=MXDPZUIOZWKRAA-PRDSJKGBSA-K
InChI=1S/C65H90N14O19S2.Lu/c1-38(80)56-64(96)73-51(63(95)75-57(39(2)81)65(97)98)37-100-99-36-50(72-59(91)47(28-40-10-4-3-5-11-40)68-52(83)32-76-20-22-77(33-53(84)85)24-26-79(35-55(88)89)27-25-78(23-21-76)34-54(86)87)62(94)70-48(29-41-15-17-43(82)18-16-41)60(92)71-49(30-42-31-67-45-13-7-6-12-44(42)45)61(93)69-46(58(90)74-56)14-8-9-19-66;/h3-7,10-13,15-18,31,38-39,46-51,56-57,67,80-82H,8-9,14,19-30,32-37,66H2,1-2H3,(H,68,83)(H,69,93)(H,70,94)(H,71,92)(H,72,91)(H,73,96)(H,74,90)(H,75,95)(H,84,85)(H,86,87)(H,88,89)(H,97,98);/q;+3/p-3/t38-,39-,46+,47-,48+,49-,50+,51+,56+,57+;/m1./s1/i;1+2

HIDE SMILES / InChI

Description

Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Originator

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
 1.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
LUTATHERA

Approved Use

LUTATHERA is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Launch Date

2018
PubMed

PubMed

TitleDatePubMed
Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.
2017 Jan 12
Lutetium Lu 177 Dotatate Approved by FDA.
2018 Apr
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
2018 Sep 10
Patents

Patents

WO2016207732A1
1

Sample Use Guides

In Vivo Use Guide
The recommended LUTATHERA® (lutetium Lu 177 dotatate) dose is 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.
Route of Administration: Intravenous
In Vitro Use Guide
SSTR-mediated uptake of 177Lu-DOTATATE by various cell lines was measured after 4 h incubation with 100 KBq/ml 177Lu-DOTATATE in the presence or in the absence of 1 μM octreotide
Name Type Language
LUTETIUM OXODOTREOTIDE LU-177
Common Name English
LUTETATE(1-)-177LU, (N-((4,7,10-TRIS((CARBOXY-.KAPPA.O)METHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL-.KAPPA.N1,.KAPPA.N4,.KAPPA.N7,.KAPPA.N10)ACETYL)-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-CYSTEINYL-L-THREONINE CYCLIC (2-7)-DIS
Systematic Name English
LUTETIUM LU 177 DOTATATE
Common Name English
177LU-DOTATATE
Common Name English
LUTETIUM DOTATATE LU-177 [ORANGE BOOK]
Common Name English
(177)LU-DOTATATE
Common Name English
LUTETIUM (177LU) OXODOTREOTIDE
INN  
INN  
Official Name English
LUTETIUM (177LU) OXODOTREOTIDE [MI]
Common Name English
LUTETIUM-177(3+), S2,S7-CYCLO(N-(4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL)-4-CHLORO-L-PHENYLALANYL-D-CYSTEINYL-4-((4S)-2,6-DIOXO-1,3-DIAZINANE-4-CARBOXAMIDO)-L-PHENYLALANYL-4-(CARBAMOYLAMINO)-D-PHENYLALANYL-L-LYSYL-L-THREONYL-L-
Systematic Name English
((177)LU-DOTA(0)-TYR(3))-OCTREOTATE
Common Name English
lutetium (¹⁷⁷Lu) oxodotreotide [INN]
Common Name English
LUTETIUM DOTATATE LU-177
Common Name English
LUTATHERA
Brand Name English
OXODOTREOTIDE LUTETIUM, LU-177
Common Name English
DOTATATE LUTETIUM LU-177
Common Name English
177LU-DOTA-TYR3-OCTREOTATE
Common Name English
LUTETIUM LU-177 DOTATATE
Common Name English
DOTA-OCTREOTATE LUTETIUM LU-177
Common Name English
OXODOTREOTIDE LUTETIUM LU-177
Common Name English
LUTETIUM DOTATATE, LU-177
Common Name English
Lutetium (177Lu) dotatate [WHO-DD]
Common Name English
DOTATATE LUTENIUM LU-177
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 271008
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
NCI_THESAURUS C129819
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
EU-Orphan Drug EU/3/07/523
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
NCI_THESAURUS C2124
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
WHO-ATC V10XX04
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
Code System Code Type Description
DAILYMED
AE221IM3BB
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
INN
10470
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
EVMPD
SUB180110
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
LACTMED
Lutetium Lu 177 Dotatate
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
MERCK INDEX
m12054
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
CAS
437608-50-9
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
PUBCHEM
76966897
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
SMS_ID
100000166133
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
RXCUI
1999335
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
DRUG CENTRAL
5275
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
NCI_THESAURUS
C95020
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID20195927
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
DRUG BANK
DB13985
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
FDA UNII
AE221IM3BB
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
PRIMARY
CAS
753443-19-5
Created by admin on Sat Dec 16 05:01:22 GMT 2023 , Edited by admin on Sat Dec 16 05:01:22 GMT 2023
ALTERNATIVE
PARENT (SALT/SOLVATE)
Structure of OXODOTREOTIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966